1. Home
  2. RVMDW vs CENX Comparison

RVMDW vs CENX Comparison

Compare RVMDW & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • CENX
  • Stock Information
  • Founded
  • RVMDW N/A
  • CENX 1995
  • Country
  • RVMDW United States
  • CENX United States
  • Employees
  • RVMDW 490
  • CENX N/A
  • Industry
  • RVMDW
  • CENX Aluminum
  • Sector
  • RVMDW
  • CENX Industrials
  • Exchange
  • RVMDW Nasdaq
  • CENX Nasdaq
  • Market Cap
  • RVMDW N/A
  • CENX N/A
  • IPO Year
  • RVMDW N/A
  • CENX 1996
  • Fundamental
  • Price
  • RVMDW $0.12
  • CENX $18.69
  • Analyst Decision
  • RVMDW
  • CENX Buy
  • Analyst Count
  • RVMDW 0
  • CENX 3
  • Target Price
  • RVMDW N/A
  • CENX $21.00
  • AVG Volume (30 Days)
  • RVMDW N/A
  • CENX 1.3M
  • Earning Date
  • RVMDW N/A
  • CENX 02-19-2025
  • Dividend Yield
  • RVMDW N/A
  • CENX N/A
  • EPS Growth
  • RVMDW N/A
  • CENX N/A
  • EPS
  • RVMDW N/A
  • CENX 3.19
  • Revenue
  • RVMDW N/A
  • CENX $2,101,699,999.00
  • Revenue This Year
  • RVMDW N/A
  • CENX N/A
  • Revenue Next Year
  • RVMDW N/A
  • CENX $7.27
  • P/E Ratio
  • RVMDW N/A
  • CENX $5.86
  • Revenue Growth
  • RVMDW N/A
  • CENX N/A
  • 52 Week Low
  • RVMDW N/A
  • CENX $9.65
  • 52 Week High
  • RVMDW N/A
  • CENX $25.39
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • CENX 47.49
  • Support Level
  • RVMDW N/A
  • CENX $17.64
  • Resistance Level
  • RVMDW N/A
  • CENX $19.08
  • Average True Range (ATR)
  • RVMDW 0.00
  • CENX 1.18
  • MACD
  • RVMDW 0.00
  • CENX 0.03
  • Stochastic Oscillator
  • RVMDW 0.00
  • CENX 46.05

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: